Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective
ConclusionsFor both biologic-naïve and experienced PsA patients, secukinumab is either a dominant or cost-effective treatment option compared with other biologics in Argentina.
Source: Value in Health Regional Issues - Category: International Medicine & Public Health Source Type: research
More News: Argentina Health | Arthritis | Enbrel | Humira | International Medicine & Public Health | Psoriasis | Psoriatic Arthritis | Remicade | Rheumatology | Stelara | Study